Structured evidence table for Algal Oil Lipid Profile Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Algal Oil Lipid Profile Randomized Trial | Despite strong biological plausibility, clinical evidence remains heterogeneous. | 4 | Egalini F (2026) | Omega-3 Polyunsaturated Fatty Acid Formulations in Cardiovascular Prevention: Balancing Clinical Efficacy, Safety, and Environmental Sustainability. |
| Algal Oil Lipid Profile Randomized Trial | While traditional low-dose mixed formulations often failed to show significant benefits, high-dose purified EPA (icosapent ethyl, 4 g/day) has demonstrated a substantial reduction in residual cardiovascular risk in specific populations. | 4 | Egalini F (2026) | Omega-3 Polyunsaturated Fatty Acid Formulations in Cardiovascular Prevention: Balancing Clinical Efficacy, Safety, and Environmental Sustainability. |
| Algal Oil Lipid Profile Randomized Trial | However, this clinical success is accompanied by a modest but consistent increase in atrial fibrillation risk at pharmacological doses, suggesting a need for better risk stratification. | 4 | Egalini F (2026) | Omega-3 Polyunsaturated Fatty Acid Formulations in Cardiovascular Prevention: Balancing Clinical Efficacy, Safety, and Environmental Sustainability. |
| Algal Oil Lipid Profile Randomized Trial | Omega-3 polyunsaturated fatty acids (ω-3 PUFAs), specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are critical modulators of cardiovascular physiology, acting through anti-inflammatory signaling, membrane remodeling, and transcriptional regulation. | 4 | Egalini F (2026) | Omega-3 Polyunsaturated Fatty Acid Formulations in Cardiovascular Prevention: Balancing Clinical Efficacy, Safety, and Environmental Sustainability. |
| Algal Oil Lipid Profile Randomized Trial | Introduction Commercial omega-7 products vary widely in fatty acid composition and chemical form, complicating direct comparison among products. | 4 | Correa M (2026) | Palmitoleic acid content and composition-based nutritional quality of commercial omega-7 oils and supplements. |
| Algal Oil Lipid Profile Randomized Trial | This study compared commercially available omega-7 sources using palmitoleic acid (POA; 16:1 n-7) and total omega-7, calculated as POA plus cis-vaccenic acid (18:1 n-7), as composition-based indicators of omega-7 nutritional quality. | 4 | Correa M (2026) | Palmitoleic acid content and composition-based nutritional quality of commercial omega-7 oils and supplements. |
Source documents